Formycon AG (FSE: FYB) and OneSource Specialty Pharma Limited (BSE: 544292, NSE: ONESOURCE) have announced a strategic manufacturing partnership for biosimilars, according to a press release. Under the agreement, OneSource will serve as a strategic manufacturing partner for Formycon, providing integrated Drug Substance (DS) and Drug Product (DP) manufacturing capabilities from its biologics facility in Bangalore, India. The collaboration combines Formycon's biosimilar development expertise with OneSource's end-to-end biologics manufacturing capabilities to support Formycon's biosimilar programs for global markets.
Dr. Stefan Glombitza, Chief Executive Officer of Formycon AG, stated: 'Reliable, scalable and cost-efficient manufacturing is a cornerstone of our FYB4Growth strategy. By adding OneSource to our network of strategic manufacturing partners, we are further strengthening our supply capabilities with a partner that meets our unwavering commitment to high standards of quality, operational excellence and cost-efficiency. Together, we aim to broaden sustainable global access to life-changing biosimilar therapies.'
Neeraj Sharma, Managing Director & CEO of OneSource Specialty Pharma, commented: 'We are delighted to partner with Formycon, one of the world's leading biosimilar developers with a proven track record of bringing high-quality biosimilars to global markets. This partnership brings together Formycon's development expertise and OneSource's integrated manufacturing capabilities to expand access to high-quality, affordable biologics for patients worldwide. It also reinforces our belief that India is uniquely positioned to serve as a global hub for the development and manufacturing of world-class biologics.'
The partnership highlights the shared commitment to advancing global access to biosimilars through reliable, high-quality, and scalable manufacturing. Achieving this requires a sustainable, cost-effective manufacturing model, which OneSource is positioned to deliver. Formycon brings a strong track record in biosimilar development and commercialization, supported by an established portfolio and a robust pipeline. OneSource complements this with an integrated biologics platform spanning cell line development through commercial fill-finish, five manufacturing facilities approved by leading global regulatory authorities, including the US FDA and EMA, and extensive expertise across biologics, sterile injectables, and drug-device combinations.
This news is significant as it underscores the growing trend of partnerships between Western biotech firms and Indian CDMOs to reduce costs and increase access to biosimilars. Biosimilars, which are follow-on products of biopharmaceutical medicines, create competition and give more patients access to biopharmaceutical therapies while reducing costs for healthcare systems. Global sales of biosimilars currently amount to around 21 billion US dollars, with analysts projecting a rise to over 74 billion US dollars by 2030. By leveraging OneSource's manufacturing capabilities, Formycon aims to strengthen its supply chain and support its FYB4Growth strategy, which focuses on geographic diversification, a smart portfolio strategy, excellence and innovation, and consistent cost efficiency.
For more information about Formycon, visit https://www.formycon.com/. Details on the FYB4Growth strategy can be found at https://www.fyb4growth.com. Information about OneSource is available at https://www.onesourcecdmo.com.
